Under the collaboration, all the products in the portfolio will continue to be marketed through affiliates in seven major European countries
Grünenthal announces joint venture collaboration with Kyowa Kirin. (Credit: Pexels from Pixabay)
Grünenthal and Kyowa Kirin have completed a deal to establish a Joint Venture Collaboration focused on Kyowa Kirin International’s established medicines portfolio.
The portfolio includes 13 brands across six therapeutic areas, with a primary focus on pain management. Some notable products in the portfolio are Abstral and PecFent, which are used for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3 for osteoporosis.
Under the collaboration, all the products in the portfolio will continue to be marketed through affiliates in seven major European countries. Additionally, the products will be distributed through a network of partners in various other territories around the world.
Grünenthal, a science-based pharmaceutical company with a global presence, and Kyowa Kirin, a speciality pharmaceutical company based in Japan, are joining forces to leverage their expertise and expand the reach of Kyowa Kirin International’s established medicines in the pain management therapeutic area. The partnership aims to strengthen the presence of these important medicines in the market and ensure patients continue to have access to these treatments.”
Grünenthal CEO Gabriel Baertschi said: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
Kyowa Kirin International president Jeremy Morgan said: “The established medicines portfolio has a proud history of delivering life-changing value for patients.
“Today’s announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality.”
With Grünenthal holding a 51% majority share in the Joint Venture Collaboration and Kyowa Kirin owning a 49% share, Grünenthal is set to fully acquire the remaining 49% share by exercising an option at the beginning of 2026.
As part of this collaboration, a new enterprise called Grünenthal Meds has been created to market Kyowa Kirin International’s established medicines portfolio. The portfolio consists of 13 brands across six therapeutic areas, with a primary focus on pain management.
Grünenthal Meds will be the branded entity responsible for marketing and distributing the medicines in all markets.